Samsung Bioepis Co,.Ltd. is engaged in provision of biopharmaceutical and biosimilar products. The company offers products such as IMRALDI, an anti-TNF biosimilar product used for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, and uveitis. Samsung Bioepis Co,.Ltd. operates as a subsidiary of Samsung Biologics Co., Ltd. The company was incorporated in 2012 and is based in Incheon, South Korea.
Headquarters
76, Songdogyoyuk-ro Yeonsu-gu Incheon
Incheon; Incheon;
Postal Code: 406840
Contact Details: Purchase the Samsung Bioepis Co,.Ltd. (Incheon) report to view the information.
Website: http://www.samsungbioepis.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service